Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

sirukumab

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Objectives Interleukin-6 (IL-6) is implicated in rheumatoid arthritis (RA) pathophysiology. Unlike IL-6 receptor inhibitors… Expand
Highly Cited
2017
Highly Cited
2017
BACKGROUND Sirukumab, a human monoclonal antibody that selectively binds to the interleukin-6 cytokine with high affinity, is… Expand
Highly Cited
2016
Highly Cited
2016
To assess the efficacy and safety of sirukumab, an anti–interleukin‐6 monoclonal antibody, for the treatment of patients with… Expand
2015
2015
This therapeutic protein–drug interaction study evaluated the disease‐mediated effect of sirukumab (anti‐interleukin 6 [anti‐IL‐6… Expand
Highly Cited
2014
Highly Cited
2014
The combination of synthetic disease-modifying anti-rheumatic drugs (sDMARDs) such as methotrexate (MTX) and biologic DMARDs… Expand
Highly Cited
2014
Highly Cited
2014
Objectives The safety and efficacy of sirukumab, an anti-interleukin-6 (IL-6) monoclonal antibody, were evaluated in a 2-part… Expand
2014
2014
Background Interleukin-6 is a pro-inflammatory cytokine that is over-expressed in LN. Objectives This proof-of-concept study… Expand
Highly Cited
2013
Highly Cited
2013
OBJECTIVE We undertook a 2-part, phase I, double-blind, placebo-controlled study to evaluate the safety and pharmacokinetics of… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
2013
2013
OBJECTIVE Sirukumab (CNTO 136) is a human mAb with high affinity and specificity for binding to interleukin-6. This Phase 1 study… Expand
Highly Cited
2011
Highly Cited
2011
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT Interleukin (IL)-6 is a cytokine known for pleiotropic and pro-inflammatory functions… Expand